Abstract
Omalizumab, is the first targeted biologic therapeutic approved for the treatment of moderate and severe persistent uncontrolled asthma.
The aim: was to evaluate the clinical efficacy and safety of Omalizumab as additive treatment in children with severe uncontrolled asthma in real clinical practice.
Materials and methods: 23 children with severe uncontrolled atopic asthma aged from 6 to 18 years were included in this study. Examination included studying clinical data, level of total IgE, eosinophil count, skin tests, spirometry, chest X-ray, oxygen saturation monitoring, Childhood Asthma Control Test, Asthma Control Test. Patients were treated with Omalizumab once every four weeks. The duration of follow-up was from 1 to 5 years.
Results: The average age of the patients was 10.5 years±2.23 (6-11 years - 34.8%, 12-17 years - 65.2%). The duration of Omalizumab therapy was different: 1-2 years-39.1% children, 3-4 years-47.8% children, more than 5 years-13.1% children. 95.6% children have demonstrated positive dynamics for 12 months of therapy with Omalizumab. 82.6% patients achieved full control of asthma symptoms. 95.6% of patients had a decrease in the amount of antiinflammatory therapy (60.9% of patients changed therapy from LABA/ICS to monotherapy with ICS in medium doses, in 26.1% children the dose of ICS in the combined LABA/ICS was reduced from high to medium), decrease in total IgE, increased physical activity, reduced exacerbations. Serious adverse events were not observed.
Conclusions: Omalizumab is effective and safe in real clinical practice as addition to baseline therapy in severe uncontrolled asthma. It lowers the risk of exacerbations, achieves of control of asthma symptoms and improves quality of children’s life.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3918.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021